Novartis: Sandoz ready to compete for Enbrel's US market
BUY, Fair Value CHF110 (+23%)
Bayer: FV reduced after adjustment to Covestro listing
NEUTRAL vs. BUY, Fair Value EUR124 vs. EUR135 (+10%)
Bayer: Covestro - Terms of listing changed
BUY, Fair Value UNDER REVIEW
Galapagos: What deal should we be looking for now?
BUY, Fair Value EUR52 vs. EUR50 (+42%)